Where does your money go?
How to get involved
Invest in our mission
Start an honor fund
Invest in our technology
Thank you to The Kuni Foundation for funding this equipment purchase!
We are so grateful for your help in our mission to make childhood cancer universally survivable!
Drug Combination Printer
This micro-volume drug testing instrument created by HP allows us to look for synergy between novel classes of non-chemotherapy and molecularly-targeted drugs in seconds. This technology reduces drug development time by months.
Systems Biology at Light Speed
Tracking Tumor Metastasis-In-A-Box
Going with the Flow
Freeze Cancer in its Tracks
Give a mouse a home…
For this naming opportunity, you will be recognized with a special engraved scroll at the entryway to our unique Kyoto-style mouse house.
Stopping the Invasion
Natural Products Drug Library
Tank it Up
Invest in our people
Named Fellowship in Pediatric Cancer Research:
Travel Award for Trainees & Scientific Sharing
Summer Student Research Internship
The Pediatric Cancer Nanocourse
Named, Endowed Chair in Childhood Cancer Research
Invest in our projects
Our mission is to make all forms of childhood cancer universally
survivable. Many of the types of cancer we study have seen little to no
treatment advancement in decades.
A Novel Treatment for Children with Anaplastic Wilms’ Tumor
To this end, we will use a combination of functional genomics, drug screening and gene expression data mining to develop a novel targeted therapy combination that is specific to anaplastic Wilms’ tumor. We will then preclinically validate this novel drug combination in vitro, ex ovo, and in vivo in order to provide a strong rationale for moving this therapeutic strategy into the clinical setting.
Engineering Forward Initiative for Childhood Cancer Therapies
Epigenetic Therapy to Overcome Checkpoint Adaptation in Rhabdomyosarcoma
The gap attributed to Pax3:Foxo1 mediated treatment resistance is estimated to be up to a 50% difference in survival over 10 years. Genetic knockdown of Pax3:Foxo1 improves chemotherapy & radiation sensitivity and reduces tumor re-establishment [PMID 24453992]. Remarkably, however, Pax3:Foxo1 can also be pharmacologically silenced at the mRNA and protein levels by entinostat, an adult phase II histone deacetylase inhibitor recently granted FDA breakthrough designation for ER+ breast cancer. In our studies, entinostat dramatically improved sensitivity to the rhabdomyosarcoma chemotherapeutic, Actinomycin-D. This latter work from our lab is in press for the journal, Genes & Development. We also have unpublished data to suggest that radiation sensitivity is dramatically improved as well. What remains to established is that entinostat will sensitize Pax3:Foxo1+ aRMS to the chemotherapies most often used in relapsed disease (our planned initial phase II strategy). The Phase I study is underway (clinicaltrials.gov NCT02780804) … the race is on to generate the data enabling the Phase II clinical trial.
The ASPS/Xp11 RCC/PEComa Cancers Consortium
We are collaborating with DFCI, The University of Utah, and the University of Miami to achieve our mission of: creating a registry for ASPS, Xp11 RCC, PEComa and EHE patients and families, generating a shareable central resource (biorepository) for cell lines and mouse models, and using robotic drug screens to discover new therapeutics (drugs) to treat ASPS, Xp11 RCC, PEComa and EHE.
The ETANTR (ETMR) Consortium
Invest in our space
We currently operate out of a 4600 squarefoot laboratory in proximity to the Silicon Forest. You can help us maintain and grow our laboratory, ultimately, accelerating our mission to make all childhood cancers uniformly survivable.